QLC5508
Sponsors
Qilu Pharmaceutical Co., Ltd.
Conditions
Advanced Prostate CancerAdvanced Solid TumorEsophageal Squamous Cell Carcinoma (ESCC)Extensive-stage Small Cell Lung CancerExtrapulmonary Neuroendocrine CarcinomaProstate Cancer
Phase 1
A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer
RecruitingNCT07198633
Start: 2025-11-05End: 2027-12-01Target: 212Updated: 2026-06-02
A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors
RecruitingNCT07256782
Start: 2025-10-24End: 2028-05-31Target: 444Updated: 2025-12-01
Phase 3
QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
RecruitingNCT07463573
Start: 2026-04-20End: 2029-07-05Target: 466Updated: 2026-04-24
QLC5508 in Participants With Metastatic Prostate Cancer
Not yet recruitingNCT07632690
Start: 2026-06-20End: 2030-11-20Target: 700Updated: 2026-06-08
A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer
Not yet recruitingNCT07802821
Start: 2026-10-15End: 2030-06-15Target: 556Updated: 2026-09-03
QLC5508 vs. Investigator's Choice Chemotherapy in Advanced Extrapulmonary Neuroendocrine Carcinoma
Not yet recruitingNCT07894211
Start: 2026-10-26End: 2030-06-30Target: 270Updated: 2026-10-26